The Motley Fool

APRIL 17, 2024

Some good news from a clinical trial conducted by Eli Lilly (NYSE: LLY) boosted the share price of the pharmaceutical giant (by 0.5%) on Wednesday, leaving several rivals in the dust. These included device makers ResMed (NYSE: RMD) , whose stock suffered a 6% blow, and AdaptHealth (NASDAQ: AHCO) , with a nearly 2% decline.

Returns 130

Returns Capital Portfolios Investors 130

The Motley Fool

MARCH 8, 2024

Eli Lilly (NYSE: LLY) stock was on quite a roll this young year, but a new development shifted that momentum on Friday. It quoted the president of the Lilly Neuroscience unit, Anne White, saying, "We are confident in donanemab's potential to offer very meaningful benefits to people with early symptomatic Alzheimer's disease."

Returns 130

Returns Portfolios Companies Investors 130

The Motley Fool

JANUARY 21, 2024

Wayne Gretzky probably had no idea just how often one statement he made would be quoted through the years. Lowe's Companies (NYSE: LOW) 2.02% 129.2% Enterprise Products Partners (NYSE: EPD) 7.54% 18.4% Bank of America (NYSE: BAC) 3.02% 60% 9. Eli Lilly (NYSE: LLY) 0.83% 101.6% Hershey 2.49% 65.1%

Banks 244

Banks Prospects Financing Finance 244

The Motley Fool

OCTOBER 31, 2023

On the downside, their counterparty in the deal, Eli Lilly (NYSE: LLY) , saw its share price slump by 2%. Shares of Beam Therapeutics (NASDAQ: BEAM) and Verve Therapeutics (NASDAQ: VERV) shot up 11% and 28%, respectively, on the day.

Stakes 130

Stakes Debt Capital Portfolios 130

The Motley Fool

FEBRUARY 6, 2024

Eli Lilly (NYSE: LLY) Q4 2023 Earnings Call Feb 06, 2024 , 10:00 a.m. The numbers you quote from the tirzepatide and semaglutide studies seem right to me. Image source: The Motley Fool. At this time, all participants are on a listen-only mode. Of course, they're not head-to-head studies.

Securities and Exchange Commission (SEC) 147

Securities and Exchange Commission (SEC) Taxes Capital Investors 147